Search

Displaying results 6201 - 6210 of 10000 in total
  1. Drug

    Allogeneic Cardiosphere-Derived Cells

    go.drugbank.com/drugs/DB15744
    Investigational

    The anti-inflammatory effects of CDC work through polarizing macrophages and restoring tissue function. … They exert their effects by secreting exosomes: nanometer-sized, membrane-bound vesicles used for the purpose of cell-cell communication.

  2. Drug

    Bentracimab

    go.drugbank.com/drugs/DB16659
    Investigational

    Bentracimab is under investigation in clinical trial NCT04286438 (Bentracimab (PB2452) in Ticagrelor-treated Patients With Uncontrolled Major or Life-threatening Bleeding or Requiring Urgent Surgery or

  3. Drug

    EVT 201

    go.drugbank.com/drugs/DB05721
    Investigational

    EVT 201 is a novel partial positive allosteric modulator of the GABAA receptor complex which is being developed as a treatment for insomnia. It is being developed by Evotec Inc.

  4. Drug

    TAK-243

    go.drugbank.com/drugs/DB15013
    Investigational

    TAK-243 is under investigation in clinical trial NCT03816319 (TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Refractory Myelodysplastic Syndrome or Chronic Myelomonocytic

  5. Drug

    ING-1

    go.drugbank.com/drugs/DB05831
    Investigational

    ING-1 is a high-affinity, human engineered trade mark monoclonal antibody that recognizes a 40 kilodalton epithelial cell adhesion molecule (EpCAM) glycoprotein that is expressed in high levels on most

  6. Drug

    GT 389-255

    go.drugbank.com/drugs/DB05894
    Experimental

    Peptimmune’s lead product GT 389-255, is a novel lipase inhibitor and fat binding hydrogel polymer conjugate for the treatment of obesity which has completed single and multiple ascending dose (SAD and

  7. Drug

    MB-07803

    go.drugbank.com/drugs/DB05053
    Investigational

    MB07803 is a second generation gluconeogenesis inhibitor for the treatment of type 2 diabetes. It is designed to block the metabolic pathway in the liver that is responsible for producing glucose.

  8. Drug

    EA-2353

    go.drugbank.com/drugs/DB18506
    Investigational

    EA-2353 is a small molecule inhibitor of kinase mediators of the Wnt pathway.

  9. Drug

    OPC-28326

    go.drugbank.com/drugs/DB05461
    Experimental

    It is currently being investigated in the treatment of peripheral vascular diseases and Raynaud's syndrome. … At low doses, OPC 28326 selectively vasodilates the femoral arterial bed due to its inhibitory action at alpha-2-adrenoceptors while having minimal action on systemic blood pressure, heart rate and coronary

  10. Drug

    Deanol

    go.drugbank.com/drugs/DB13352
    Investigational

    Deanol has been used in the treatment of attention deficit-hyperactivity disorder (ADHD), Alzheimer's disease, autism, and tardive dyskinesia. … Deanol is commonly referred to as 2-(dimethylamino)ethanol, dimethylaminoethanol (DMAE) or dimethylethanolamine (DMEA). It holds tertiary amine and primary alcohol groups as functional groups.